Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDC42 effector protein 1 (CDC42EP1)
- Target
- CDC42EP1
- Molecular classification
- Other (effector protein), Adapter/scaffold protein, Cytoskeletal regulator
01
Overview
CDC42 effector protein 1 (CDC42EP1) is a member of the Borg (binder of Rho GTPases) family of effector proteins that interact with the Rho GTPase CDC42. It plays a critical role in regulating actin cytoskeleton dynamics, cell shape, and migratory capacity by binding to CDC42 in a GTP-dependent manner via its CRIB domain. CDC42EP1 is primarily expressed in bone marrow, including bone marrow stromal and endothelial cells, and is secreted into serum. Its functions are mediated through interactions with actin and septin cytoskeletal elements, contributing to processes such as angiogenesis and embryonic cell migration. Functional disruption of CDC42EP1 has been linked to impaired cell migration, abnormal cardiac development, and altered angiogenesis. Recent studies also associate CDC42EP1 with cancer, particularly as a potential driver in oral tongue squamous cell carcinoma, highlighting its influence on cell morphology and tumorigenesis[1][2][3][4].
- Other names
- BORG5MSE55CEP155 kDa bone marrow stromal/endothelial cell proteinbinder of Rho GTPases 5serum protein MSE55serum constituent protein
02
Biological functions
Actin cytoskeleton organizationCell migrationCell shape regulationAngiogenesisActomyosin contractility
03
Disease associations
Cancer (oral tongue squamous cell carcinoma)Developmental disorders (acromelic frontonasal dysostosis)Cardiovascular disease (role in angiogenesis)Other (potential but not well established for other diseases)
Beyond the preview
Go deeper on CDC42 effector protein 1 (CDC42EP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDC42 effector protein 1 (CDC42EP1).